Imaging Procedure Using ALA in Finding Residual Tumor in Grade IV Malignant Astrocytoma
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Brain Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 3/7/2019 |
| Start Date: | August 18, 2008 |
| End Date: | May 2019 |
Fluorescence-Guided Detection of Malignant Gliomas: A Dose Ranging Study Using 5-Aminolevulinic Acid (ALA) Induced Protoporphyrin (PpIX) in a Multicenter Phase II Clinical Trial
RATIONALE: Imaging procedures that use aminolevulinic acid may help find and diagnose
residual tumor in patients with grade IV malignant astrocytoma who are undergoing surgery to
remove the tumor.
PURPOSE: Our primary long-term goal is to improve the completeness of surgical resection of
malignant brain tumor through image- guided fluorescence localization. We hypothesize that
the use of qualitative fluorescence imaging and point PpIX concentration quantification will
enable more complete tumor resection than normal direct (i.e., white light) visualization,
and thereby improve patient survival.
residual tumor in patients with grade IV malignant astrocytoma who are undergoing surgery to
remove the tumor.
PURPOSE: Our primary long-term goal is to improve the completeness of surgical resection of
malignant brain tumor through image- guided fluorescence localization. We hypothesize that
the use of qualitative fluorescence imaging and point PpIX concentration quantification will
enable more complete tumor resection than normal direct (i.e., white light) visualization,
and thereby improve patient survival.
OBJECTIVES:
Primary
- Assess 2 doses of 5-ALA, 10kg/mg and 20kg/mg, to determine the optimum ALA dose in terms
of both sensitivity and specificity for residual tumor. We will compare residual tumor
detection by both in vivo qualitative and quantitative fluorescence imaging using
histology of the biopsied tissue as the gold standard.
Secondary
- Assess the correlation between the recorded in vivo qualitative assessment of
fluorescence signal from the neurosurgeon with the post-surgical (i.e., ex vivo)
absolute PpIX concentration detected both intraoperatively and in ex vivo tissue
biopsies.
Tertiary
- To determine the association between the presence of fluorescence in the surgical cavity
and the post-operative image enhancement on MRI. This includes the relationship between
the amount and location of residual tumor detected by fluorescence, PpIX concentration,
and intra-operative frameless stereotaxy following maximal resection versus the amount
and location of tumor imaged post-operatively via CT and/or MRI.
OUTLINE: This study will enroll evaluable patients undergoing surgical resection of
malignant, grade IV gliomas in both of two groups: those with , newly diagnosed GBM and those
with recurrent GBM. Patient, in each group (primary vs recurrent GBM) will be randomized to
one of 2 levels of ALA dose (10 and20 mg/kg) to be given orally at 6 hours prior to
anticipated midpoint of surgery.
Patients who have consented to this protocol will be randomly assigned to one of two ALA dose
groups. Randomization will be stratified by whether the tumor is newly diagnosed (i.e. de
novo) or recurrent. The data center will prepare sealed, opaque envelopes with the randomized
assignment to ALA dose and administration time and notify the pharmacy of the trial site so
that so that the correct ALA dose can be prepared.
- Arm I: Newly diagnosed GBM patients receive oral aminolevulinic acid(10mg/kg)at 6 hours
before the midpoint of surgery.
- Arm II: Newly diagnosed GBM patients receive oral aminolevulinic acid (20mg/kg)at 6
hours before the midpoint of surgery.
- Arm III: Recurrent GBM patients receive oral aminolevulinic acid (10mg/kg)at 6 hours
before the midpoint of surgery.
- Arm IV: Recurrent GBM patients receive oral aminolevulinic acid (20mg/kg)at 6 hours
before the midpoint of surgery.
For both patients with new and recurrent disease, biopsies will be taken at up to six sites
identified by the surgeon: in the tumor center, tumor edge, area surrounding the tumor (if
safe), areas seen to fluoresce intraoperatively and an area with MR enhancement outside the
tumor region (if this can be accomplished safely). Prior to collecting these biopsies
readings will be taken at the biopsied location with the PpIX point probe by the surgeon. For
each of the 6 biopsies, they will be divided into 3 parts and distributed for further
analysis as follows: one portion will be sent to the pathologist for assessment of tumor
percentage, one portion will be evaluated by the Division of Biophysics at the University of
Toronto for PpIX concentration and the other for assessment of fluorescence.
Primary
- Assess 2 doses of 5-ALA, 10kg/mg and 20kg/mg, to determine the optimum ALA dose in terms
of both sensitivity and specificity for residual tumor. We will compare residual tumor
detection by both in vivo qualitative and quantitative fluorescence imaging using
histology of the biopsied tissue as the gold standard.
Secondary
- Assess the correlation between the recorded in vivo qualitative assessment of
fluorescence signal from the neurosurgeon with the post-surgical (i.e., ex vivo)
absolute PpIX concentration detected both intraoperatively and in ex vivo tissue
biopsies.
Tertiary
- To determine the association between the presence of fluorescence in the surgical cavity
and the post-operative image enhancement on MRI. This includes the relationship between
the amount and location of residual tumor detected by fluorescence, PpIX concentration,
and intra-operative frameless stereotaxy following maximal resection versus the amount
and location of tumor imaged post-operatively via CT and/or MRI.
OUTLINE: This study will enroll evaluable patients undergoing surgical resection of
malignant, grade IV gliomas in both of two groups: those with , newly diagnosed GBM and those
with recurrent GBM. Patient, in each group (primary vs recurrent GBM) will be randomized to
one of 2 levels of ALA dose (10 and20 mg/kg) to be given orally at 6 hours prior to
anticipated midpoint of surgery.
Patients who have consented to this protocol will be randomly assigned to one of two ALA dose
groups. Randomization will be stratified by whether the tumor is newly diagnosed (i.e. de
novo) or recurrent. The data center will prepare sealed, opaque envelopes with the randomized
assignment to ALA dose and administration time and notify the pharmacy of the trial site so
that so that the correct ALA dose can be prepared.
- Arm I: Newly diagnosed GBM patients receive oral aminolevulinic acid(10mg/kg)at 6 hours
before the midpoint of surgery.
- Arm II: Newly diagnosed GBM patients receive oral aminolevulinic acid (20mg/kg)at 6
hours before the midpoint of surgery.
- Arm III: Recurrent GBM patients receive oral aminolevulinic acid (10mg/kg)at 6 hours
before the midpoint of surgery.
- Arm IV: Recurrent GBM patients receive oral aminolevulinic acid (20mg/kg)at 6 hours
before the midpoint of surgery.
For both patients with new and recurrent disease, biopsies will be taken at up to six sites
identified by the surgeon: in the tumor center, tumor edge, area surrounding the tumor (if
safe), areas seen to fluoresce intraoperatively and an area with MR enhancement outside the
tumor region (if this can be accomplished safely). Prior to collecting these biopsies
readings will be taken at the biopsied location with the PpIX point probe by the surgeon. For
each of the 6 biopsies, they will be divided into 3 parts and distributed for further
analysis as follows: one portion will be sent to the pathologist for assessment of tumor
percentage, one portion will be evaluated by the Division of Biophysics at the University of
Toronto for PpIX concentration and the other for assessment of fluorescence.
Inclusion Criteria:
- Tumor Pathology: Newly diagnosed or recurrent malignant gliomas WHO grade IV
- Location: Supratentorial
- Resection: Tumor must be judged suitable for resection on the basis of imaging
studies.
- Consent: Patients must be able to give written, informed consent as approved by the
local IRB
- Newly Diagnosed Tumors: Patients with newly diagnosed Grade IV glioma who have had not
been previously treated with cranial radiation therapy
- Recurrent Tumors: Patients with recurrent Grade IV gliomas who have failed cranial
radiation therapy
Exclusion Criteria:
- Pregnant women or those who are breast feeding
- Individuals with history of cutaneous photosensitivity, porphyria, hypersensitivity to
porphyrins, photodermatosis, exfoliative dermatitis
- Individuals with history of liver disease in last 12 months
- Individuals with AST, ALT, ALP, or bilirubin >2.5x normal upper limit any time during
the previous 2 months
- Individuals with plasma creatinine>180 μmol/L
- Individuals who are unable to comply with photosensitivity precautions
- Individuals without a grade IV glioma
We found this trial at
1
site
Cleveland, Ohio 44106
Click here to add this to my saved trials
